INTRODUCTION
============

The emergence of drug-resistant tumor cells continues to be a major problem confronting advances in cancer chemotherapy. Resistance to the various classes of anti-tumor agents ([@B21]) has been suggested to involve reduced drug accumulation and/or retention, conformational changes and/or over production of the target enzyme, and reduced activation and/or increased catabolism of drug. Doxorubicin (DOX) is a clinically effective anti-tumor agent against a spectrum of neoplastic diseases ([@B12]; [@B75]). Although DOX is an inhibitor of topoisomerase II (topo II), multifactorial mechanisms are involved in the cytotoxic response ([@B90]; [@B72]; [@B3]; [@B28]). Pioneering studies of [@B62] and [@B4] established that reduced drug accumulation in tumor cells is a major mechanism involved in resistance to clinically important anti-tumor agents, e.g., anthracyclines and vinca-alkaloids. The overexpression of P-glycoprotein (PGP) in resistant cells, which mediates energy dependent drug efflux across a concentration gradient and is responsible for reduced drug accumulation, was originally described by [@B71]. The cross-resistance to anti-tumor drugs of diverse structure and/or mechanism of action ([@B32]; [@B18]) mediated by PGP is now termed multidrug resistance (MDR). MDR in the absence of overexpression of PGP has been demonstrated to be due to the MDR related protein (MRP), which like PGP also belongs to the ATP-binding cassette (ABC) superfamily of membrane proteins ([@B13]; [@B20]).

MODULATION OF DRUG RESISTANCE BY CHEMOSENSITIZERS
=================================================

Reduced drug accumulation to anti-tumor drugs of diverse structure and mechanism of action has led to the identification of agents that can potentially sensitize tumor cells with the MDR phenotype. The original reports on modulation of MDR by calcium blockers, e.g., verapamil ([@B91]; [@B96]) or calmodulin inhibitors, e.g., trifluoperazine (TFP; [@B96]; [@B42]) has been confirmed subsequently by other laboratories in a variety of model systems ([@B36]). Excellent reviews on compounds modulating the MDR phenotype has been published, and sensitization of drug-resistant pre-clinical tumor models *in vivo* has been observed ([@B96]; [@B49]; [@B36]). The mechanism of action of the "chemosensitizers" in MDR cells is suggested to involve binding to PGP which results in increased drug accumulation and consequently cytotoxicity. While these chemosensitizers do indeed increase drug accumulation, concentrations of the anti-tumor agent required in resistant cells are significantly higher than those required by the wild-type (sensitive) cells to achieve equivalent cell kill. Based on the promise from pre-clinical studies, clinical trials have evaluated these agents to sensitize drug refractory tumors ([@B39]; [@B73]) but results with a potent inhibitor of PGP indicate that modulation of drug resistance or enhanced clinical activity is not realized ([@B11]; [@B68]).

Most studies on modulation of MDR have relied on tumor models with high levels of resistance making it difficult to ascertain whether the resistance to anthracyclines and vinca alkaloids was exclusively due to overexpression of PGP. In addition, the observation that resistance to lipophilic anthracyclines was observed without apparent differences in drug accumulation between sensitive and resistant cells suggested a role for alternate mechanisms of resistance ([@B44], [@B46]). To assess the central role for PGP and probe mechanisms of resistance to DOX we developed progressively DOX-resistant (5- to 40-fold) cell lines of L1210 mouse leukemia and B16-BL6 mouse melanoma ([@B45]; [@B43]). Studies with these progressively resistant tumor models revealed that while the IC50 for DOX alone was higher with increasing resistance (0.25--5 μM), significantly lower concentrations of DOX (0.08--0.7 μM) were required in the presence of a non-cytotoxic concentration (5 μM) of the calmodulin inhibitor TFP to achieve equivalent cell kill ([@B43]; [@B49]). In the progressively DOX-resistant L1210 cells expression of the MDR phenotype was observed only at \>10-fold but not at fivefold resistance to DOX and role of PGP in these progressively DOX-resistant cells revealed that: (a) effects of PGP on drug accumulation were correlative with vincristine (VCR) rather than DOX resistance ([@B48], [@B39]); and (b) the modulation by TFP of VCR but not DOX cytotoxicity was due to effects on drug accumulation ([@B47], [@B48]). Based on the lack of correlation between cellular DOX levels and cytotoxic response, using the progressively DOX-resistant L1210 model system, nuclear levels of DOX were determined following treatment with the IC50 of DOX in the absence or presence of 5 μM TFP ([@B47]). Results revealed that significantly higher nuclear levels of DOX were required in the resistant compared to the parental sensitive cells to achieve equivalent cytotoxicity, suggesting that alterations in topo II, a putative target of DOX may be involved ([@B47]).

TOPOISOMERASE II AND DRUG RESISTANCE
====================================

The topoisomerases alter DNA topology for the efficient processing of genetic material ([@B14]; [@B82]; [@B97]; [@B37]). The two well characterized topoisomerases, topoisomerase I (topo I) and topo II, which are essential for DNA metabolism are also the targets for the clinically effective anti-tumor agents, e.g., analogs of camptothecin (topotecan, irinotecan), DOX, daunorubicin, etoposide (VP-16), or teniposide ([@B14]; [@B82]; [@B97]; [@B37]). Eukaryotic topo I catalyzes DNA relaxation via a transient single stranded DNA break while topo II will produce a transient double stranded break for the passage of double stranded DNA segments ([@B14]; [@B82]; [@B97]; [@B37]). Anti-cancer drugs which interact with topoisomerases and produce DNA strand breaks, involves the stabilization of a ternary complex with DNA. The single or double stranded break induced by topo II, involves linkage to the 5′-phosphoryl end of the broken DNA, with the 5′ broken end protruding precisely four bases with a double strand break ([@B14]; [@B82]; [@B97]; [@B37]). The mechanism of DNA strand breakage induced by topo II inhibitors is based on the stabilization of a cleavable complex which is normally a transient reaction intermediate ([@B14]; [@B37]). The cleaved intermediate can be either a single strand or double strand break. Drugs which are topo II inhibitors exert their effects possibly by inhibiting the rejoining step in the breakage-rejoining cycle, thus shifting the equilibrium toward a cleavable complex ([@B14]; [@B37]). The agents which inhibit topo II and stabilize cleavable complex formation can be intercalative, e.g., DOX, amsacrine (m-AMSA), mitoxantrone, or non-intercalative, e.g., VP-16, teniposide (VM-26), and isoflavone derivative genistein ([@B14]; [@B82]; [@B97]; [@B37]). Mammalian topo IIα (170 kDa) and topo IIβ (180 kDa) isozymes exhibit similar catalytic, but different biologic, activities. Whereas topo IIα is associated with cell division, topo IIβ is involved in differentiation ([@B19]; [@B29]; [@B100], [@B99]). The 170 kDa topo II isoform is encoded on chromosome 17q21-22 while the 180 kDa topo II isoform is encoded on chromosome 3p24 ([@B14]; [@B97]). As a target for anti-cancer agents, there is more information on the interaction with the 170 kDa topo IIα protein, although a possible role for alterations in the 180 kDa topo IIβ isoform in mitoxantrone-resistant and m-AMSA-resistant HL-60 cells has been reported ([@B51]; [@B14]; [@B37]; [@B55]). A number of *in vitro* studies using purified or recombinant topo II enzyme have addressed determinants of drug interaction with topo II ([@B38]; [@B14]; [@B82]; [@B97]; [@B37]), and in cell systems the focus has been on enzyme levels as the determinant of drug action ([@B38]; [@B14]; [@B82]; [@B97]; [@B37]). The proliferative state of tumor cells is also an important determinant of sensitivity to inhibitors of topo II, and a correlation exists between proliferation, cell cycle stage and cytotoxicity ([@B76]; [@B92]; [@B33]; [@B24]).

Resistance to inhibitors of topo II reported in a number of tumor model systems is also prevalent in clinically refractory tumors ([@B14]; [@B37]). Based on the evaluation of tumor models with intrinsic or acquired resistance to the topo II inhibitors, as well as cell lines selected for resistance which express decreased levels of topo II ([@B14]; [@B37]) it has been proposed that levels of topo II are an important determinant of drug sensitivity. Although the levels of enzyme are obviously critical, there are several examples wherein drug sensitivity is not correlative with the 170 kDa topo IIα protein level ([@B47], [@B41]; [@B14]; [@B82]; [@B97]; [@B37]). Alternatively, altered sub-cellular distribution of the 170 and 180 kDa isoforms may also be involved with insensitivity to topo II inhibitors ([@B35]; [@B58]; [@B74]; [@B22]; [@B34]; [@B101]). While the identification of a mutant enzyme associated with drug resistance has been reported ([@B94]; [@B82]) an analysis of leukemic cells from patients who have relapsed from etoposide or teniposide therapy revealed that resistance does not have to be associated with mutations in the topo II gene ([@B23]). Also mutations identified in cultured cell lines were not found in the patient samples ([@B23]). Point mutations similar to those observed with topo IIα in m-AMSA-resistant cell lines ([@B56]) has been reported in patients with small cell lung cancer treated with etoposide ([@B70]). In addition to these mutations that have possible relevance to patient tumors refractory to therapy, several other mutations in topo IIα and β (induced or observed in drug-resistant tumor models) have been described that can confer resistance to drugs that target the enzyme ([@B17]). While studies with these mutant forms of topo II are informative, their functional role remains controversial, since they are generally not observed in patients with tumors that are clinically resistant to drugs that target the enzyme.

ANTHRACYCLINES, TOPOISOMERASE IIα, AND BREAST CANCER
====================================================

The recognition that topo IIα is a putative target of DOX, a clinically active anthracycline in the treatment of breast cancer, has led to several reports correlating anthracycline sensitivity with topo IIα expression. Major focus has been on human epidermal growth factor receptor 2 (HER2) and topo IIα expression based on their localization in chromosome 17 as well as determinants of sensitivity to trastuzumab and anthracyclines, respectively. Indeed several reports have established expression of topo IIα in predicting sensitivity to adjuvant anthracycline therapy ([@B78]; [@B5]; [@B59]; [@B27]; [@B30]; [@B77]; [@B79]). The evaluation of tissue inhibitor of metalloproteinase (TIMP-1) with HER2 or topo IIα has also suggested that a HT profile (HER2 amplified and/or TIMP-1 negative) or 2T profile (topo IIα aberrant and/or TIMP-1 negative) with substantial reduction in mortality but not relapse free survival events following adjuvant anthracycline containing therapy ([@B31]; [@B54]). Overall, while topo IIα expression is possibly a determinant of response to anthracycline containing therapy, robust assay methodology for topo IIα and well defined prospective clinical trials will establish the predictive value.

PHOSPHORYLATION OF TOPOISOMERASE II
===================================

The proliferation and cell cycle phase dependent post-translational modification by phosphorylation of the 170 and 180 kDa topo II protein ([@B53]; [@B69]; [@B89]; [@B6]; [@B7]; [@B63], [@B64]), is also linked to increased enzyme activity and DNA cleavable complex formation ([@B53]; [@B69]; [@B89]; [@B6]; [@B7]; [@B63], [@B64]). Since phosphorylation of topo II during the cell cycle regulates activity of the enzyme ([@B1]; [@B87]; [@B88]; [@B8], [@B10]; [@B9]; [@B98]), the role of altered topo II phosphorylation in drug resistance has been studied. [@B95] reported hyperphosphorylation of topo II in etoposide-resistant cells based on phosphorylation normalized for a 10-fold reduced enzyme level in the etoposide-resistant subline compared to parent cells. Since the phosphorylation of topo II is essential for catalytic events of unknotting and decatenation during cell replication, the observed hyperphosphorylation could represent a compensatory event for the reduced protein level. The topo IIα in these etoposide-resistant cells has a Ser861-Phe mutation, suggesting that these cells which hyperphosphorylate topo IIα, also express mutant serine residue ([@B67]). Hypophosphorylation of topo IIα in the teniposide-resistant cells was \>twofold compared to the parental cells, with serine being the primary phosphorylated amino acid in the sensitive or resistant cells ([@B15]). Subsequent studies by [@B83], [@B85] in etoposide-resistant K562 human leukemia cells have suggested that hypophosphorylation of topo IIα in these cells is due to decreased levels of the protein kinase C isoform ß~II~. Studies *in vitro* using *Drosophila melanogaster* topo II have demonstrated that phosphorylation of topo II by casein kinase (CK) II and protein kinase C can decrease drug stabilized DNA cleavable complex and increase DNA religation, suggesting that phosphorylation can confer relative drug resistance ([@B26]). While this effect may be due to the simultaneous use of two different kinases, a role for site specific phosphorylation differences was not discussed. Phosphorylation of topo IIα by CKII has also been reported to not affect the DNA relaxing or DNA unknotting activity ([@B65]). In contrast to these reports we have demonstrated, following metabolic labeling of cells with \[^32^P\]-orthophosphoric acid, the hypophosphorylation of 170 kDa topo II in the absence of any decrease in steady state topo II protein levels in three different model systems resistant to topo II inhibitors ([@B47], [@B40], [@B41]).

FUNCTIONAL ROLE FOR INTRACELLULAR CALCIUM AND SITE-SPECIFIC PHOSPHORYLATION OF TOPOISOMERASE IIα
================================================================================================

Potential mechanisms affecting reversibility of the drug-induced DNA cleavable complex ([@B57]) have been reported, and in resistant sublines a specific role for cleavable complex instability has been suggested ([@B25]; [@B84]). The incubation of Chinese hamster DC3F cells in calcium-free medium or chelation of extracellular calcium with \[ethylenebis(oxyethylenenitrilo)\]tetraacetic acid (EGTA) has been reported to protect against the cytotoxicity of VP-16 ([@B2]). However, under these same conditions, VP-16-induced DNA single strand break frequency in calcium-depleted cells was reported to be comparable to control cells ([@B2]). The amount of phosphorylated topo IIα in cells is obviously a balance between kinase and phosphatase activity, and our data on hypophosphorylated topo IIα in etoposide-resistant cells may be linked to enhanced phosphatase activity. We have previously reported that okadaic acid an inhibitor of protein phosphatases 1 and 2A does not affect the cytotoxicity of the topo II inhibitor DOX ([@B61]). The activity of protein phosphatase 2B (calcineurin) is enhanced following phosphorylation by calcium-calmodulin protein kinase II ([@B52]; [@B86]) or suppressed by calmodulin inhibitors ([@B66]). Thus, enhanced phosphorylation of topo IIα ([@B60]) in the presence of the inhibitors of calcium-calmodulin regulated processes, e.g., TFP or 1-\[*N*,*O*-bis(1,5-isoquinolinesulfonyl)-*N*-methyl-[L]{.smallcaps}-tyrosyl\]-4-phenylpiperazine (KN-62) possibly involves inhibition of calcineurin activity, which leads to potentiation of DNA cleavable complex formation and cytotoxicity of topo II inhibitors.

Based on the potentiation of DOX cytotoxicity and DNA damage by TFP and other inhibitors of calcium-calmodulin regulated cellular events we sought to determine whether intracellular calcium could be involved in affecting DNA damage induced by drugs that target topo II. Manipulating intracellular "free" calcium was achieved with the chelator ([@B41]) 1,2-bis(*o*-aminophenoxy)ethane-N,N,N′,N′,-tetraacetic acid tetra(acetoxymethyl) ester (BAPTA-AM). In wild-type cells pre-treatment with BAPTA-AM followed by the topo II inhibitor etoposide (VP-16) led to significant reductions in drug stabilized DNA cleavable complex formation and cytotoxicity ([@B41]). These results on reduced DNA cleavable complex formation following buffering of intracellular calcium, in general support the original observation of Osheroff and Zechiedrich who reported that in experiments with the purified enzyme *in vitro*, calcium was able to promote high levels of *D. melanogaster* topo II-mediated DNA cleavage ([@B80]; [@B81]). Also, pre-treatment of wild-type cells with BAPTA-AM led to hypophosphorylation of topo IIα ([@B41]). In order to determine whether the hypophosphorylation of topo IIα was site-specific, we carried out 2D mapping with tryptic digests of immunoprecipitated topo IIα from in DOX-resistant or wild-type cells pre-treated with BAPTA-AM ([@B41]; [@B16]). Interestingly, we found that site specific hypophosphorylation of topo IIα in DOX-resistant or wild-type cells pre-treated with BAPTA-AM was comparable ([@B41]; [@B16]). Using liquid chromatography-tandem mass spectrometry, we identified the hypophosphorylated site as serine 1106 in topo IIα ([@B16]).

To establish the functional role for serine 1106 in topo IIα, mutation of serine 1106 to alanine (S1106A) was carried out and found to abrogate phosphorylation of the phosphopeptides that were found either in the DOX-resistant cells or wild-type cells treated with BAPTA-AM. Using purified wild-type or mutant (S1106A) topo IIα expressed in BJ201 cells, we observed decreased decatenation activity as well as etoposide stabilized DNA cleavable complex formation with the mutant enzyme ([@B16]). A functional role *in vivo* for serine 1106 in resistance to inhibitors of topo II was also established using the yeast system wherein resistance to the cytotoxic effects of etoposide and m-AMSA was observed ([@B16]).

Since serine 1106 is flanked by CKI consensus sequences, and phosphorylation of this site is regulated by calcium, we probed the effect of inhibitors of CKI ([@B50]). Treatment with CKI-7 or IC261 that inhibit CKI activity, both hypophosphorylation of serine 1106 and decreased etoposide stabilized DNA cleavable complex formation was observed, suggesting a potential role for CKI phosphorylation of topo IIα ([@B50]). In the CKI family, a functional role for calcium regulatable CKIδ and/or CKIε in phosphorylating serine 1106 and affecting drug stabilized topo II DNA cleavable complex formation was established using small interfering RNA (siRNA) that target these isozymes of CKI ([@B50]). Although a precise role for site specific hypophosphorylation of topo IIα and resistance to inhibitors of topo II in patient tumors has not been established, in our preliminary studies with early passage cultures of acute myeloid leukemia and non-small cell lung cancer from patients, we have observed a correlation of site specific hypophosphorylation of topo IIα and decreased drug stabilized DNA cleavable complex formation and/or cytotoxicity with inhibitors that target topo II.

In addition to phosphorylation, other post-translational modifications of topo II include sumoylation and ubiquitination ([@B17]). Sumoylation of topo II that is induced by inhibitors targeting the enzyme also affects cellular localization ([@B17]). A role for ubiquitination-proteasome pathway in regulating enzyme function has also been reported ([@B17]). Interestingly, in human non-small cell lung carcinoma cells, proteasome inhibition with, e.g., MG-132 following treatment with etoposide leads to enhanced apoptosis and decreased arrest of cells in the G~2~+M boundary, without apparent alteration in degradation of topo II ([@B93]). In contrast, pre-treatment with the proteasome inhibitor followed by etoposide leads to decreased apoptosis, possibly due effects on apoptotic signaling ([@B93]). Neither, pre- or post-treatment with the proteasome inhibitor affected DNA damage induced by etoposide, suggesting that downstream events, e.g., apoptotic response may be another strategy to enhance anti-tumor activity of topo II inhibitors.

FUTURE DIRECTIONS
=================

In summary, it is apparent that multifactorial mechanisms govern the sensitivity of tumor cells to the DNA damaging and cytotoxic effects of clinically useful inhibitors of topo II. Much progress has been made in identifying agents and developing strategies for enhancing cellular accumulation of topo II inhibitors in tumors with the MDR phenotype. However, differences between "acquired" and "intrinsic" resistance as well as insights on mechanisms that lead to reduced activity of topo II or compromised activation of cell death pathways in tumors from patients resistant to clinically active topo II inhibitors is an underexplored area. Thus, development of targeted drugs that can activate topo II activity and cell death pathways without enhancing treatment-induced toxicity, have considerable potential in combination therapy for clinically improving the anti-tumor efficacy of topo II inhibitors.
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